Swayampakula Ramakanth, an analyst from H.C. Wainwright, reiterated the Buy rating on Precigen. The associated price target remains the same with $8.50.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Swayampakula Ramakanth has given his Buy rating due to a combination of factors including the recent FDA approval of Papzimeos, which exceeded expectations by being announced earlier than anticipated. The approval covers a broad indication for recurrent respiratory papillomatosis, potentially benefiting approximately 27,000 adult patients in the U.S. The favorable label, which includes impressive durability data and a broad indication, strengthens the drug’s market potential.
Additionally, the financial outlook for Papzimeos is promising, with projected sales of $15 million in the fourth quarter of 2025. The company’s strategic plans for launch, including targeting key Integrated Delivery Networks and community hospitals, are expected to capture a significant portion of the prescribing physician base. The valuation of Precigen’s stock is supported by a risk-adjusted net present value analysis, leading to a price target of $8.50 per share. Despite potential risks such as clinical, regulatory, and commercial challenges, the overall prospects for Papzimeos and Precigen’s strategic positioning justify the Buy rating.
Ramakanth covers the Healthcare sector, focusing on stocks such as Unicycive Therapeutics, Corcept Therapeutics, and Precigen. According to TipRanks, Ramakanth has an average return of 12.1% and a 40.80% success rate on recommended stocks.
In another report released yesterday, Citizens JMP also maintained a Buy rating on the stock with a $8.00 price target.